Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Anika Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $182.6 Mil.
Anika Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics EV-to-EBIT Related Terms
Anika Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's EV-to-EBIT falls into.
Anika Therapeutics's current Enterprise Value is $265.7 Mil.
Anika Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (ANIK) has a EV-to-EBIT of -51.89 as of Sep. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Anika Therapeutics and its competitors. According to the industry distribution chart, Anika Therapeutics ranks #999999 out of 681 companies in the Drug Manufacturers industry.
Is Anika Therapeutics' EV-to-EBIT too high?
Anika Therapeutics' current EV-to-EBIT is -51.89. Based on the distribution chart, Anika Therapeutics ranks #999999 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anika Therapeutics has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' EV-to-EBIT compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #999999 out of 681 companies for EV-to-EBIT. This places Anika Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.89, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current EV-to-EBIT is -51.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Fairly Valued. The stock's GF Value™ is $19.25, compared to a current price of $20.84 — trading 8.3% above its estimated fair value. The current EV-to-EBIT is -51.89. Anika Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current EV-to-EBIT is -51.89 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (ANIK) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued.
The current stock price of $20.84 is trading 8.3% above its estimated GF Value™ of $19.25.
GuruFocus considers Anika Therapeutics to be Fairly Valued.
Key valuation signals for ANIK:
EV-to-EBIT: -51.89
GF Value™: $19.25 vs. price of $20.84 (8.3% above fair value)
No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
61GF Score
Get the complete analysis for ANIK
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIK has been successfully added to your 
